In a report released today, Dylan Van Haaften from Stifel Nicolaus maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target of €153.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Dylan Van Haaften’s rating is based on several key considerations. Despite some challenges, Merck KGaA’s recent quarterly results were in line with expectations, particularly in terms of top-line revenue and EBITDA. The company has shown encouraging progress in its Life Sciences Process Solutions segment, which experienced strong organic growth driven by a recovery in pharmaceutical production demand.
While there are some headwinds, such as foreign exchange impacts and tariff uncertainties, the company’s guidance adjustments reflect a cautious but strategic approach to navigating these challenges. The Healthcare segment also demonstrated positive growth, and the Electronics division, although facing some profitability concerns, showed modest growth due to AI-driven demand. These factors, combined with a favorable upside to the price target, underpin the Buy rating given by Dylan Van Haaften.
In another report released on May 12, Barclays also maintained a Buy rating on the stock with a €160.00 price target.